3A8 [CMCC #11066]細(xì)胞
數(shù)量： 大量
ATCC Number： HB-12024?
運(yùn)輸方式： 凍存運(yùn)輸
是否是腫瘤細(xì)胞： 0
物種來源： 小鼠
生長狀態(tài)： 懸浮生長
細(xì)胞形態(tài)： **樣
**類型： IgG2b
3A8 [CMCC #11066]細(xì)胞Designations: 3A8 [CMCC #11066]
Depositors: Chiron Corp.
Isotype: IgG2b
Biosafety Level: 1
Shipped: frozen
Medium & Serum: See Propagation
Growth Properties: suspension
Organism: Mus musculus (B cell); Mus musculus (myeloma) deposited as mouse (B cell); mouse (myeloma)
Morphology: lymphoblast
3A8 [CMCC #11066]細(xì)胞Source: Cell Type: hybridoma: B lymphocyte;
Cellular Products: immunoglobulin; monoclonal antibody; against human CD40
Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Comments: Animals were immunized with SF9 insect cells expressing recombinant human CD40.
Spleen cells were fused with Sp2/0 myeloma cells.
The antibody is capable of binding to human CD40 antigen located on the surface of human B cells.
Propagation: 3A8 [CMCC #11066]細(xì)胞ATCC complete growth medium: Iscove's modified Dulbecco's medium with 4 mM L-glutamine adjusted to contain 1.5 g/L sodium bicarbonate supplemented with 1% OPI (0.15 mg/ml oxaloacetate, 0.05 mg/ml pyruvate, 0.0082 mg/ml bovine insulin), 90%; heat-inactivated fetal bovine serum, 10%
Temperature: 37.0°C
Subculturing: Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 1 X 10 exp5 viable cells/ml.
Maintain cell density between 1 X 10 exp5 and 1 X 10 exp6 viable cells/ml.
Preservation: culture medium 95%; DMSO, 5%
Related Products: Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2005
References: 40220: de Boer M, Conroy LB. 3A8 [CMCC #11066]細(xì)胞Anti-CD40 monoclonal antibodies capable of blocking B-cell activation. US Patent 5,677,165 dated Oct 14 1997
